Zevra Therapeutics, Inc. ZVRA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Zevra Therapeutics, Inc. (ZVRA) is a healthcare company listed in the US with a market value of about $540M. In the twelve months to September 30, 2026 it had revenue of $148M and net income of $75M, a net margin of 50.7%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 7.4, a price to free cash flow of 14.1, 5-year revenue growth of 52% a year, a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
About Zevra Therapeutics
Zevra Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $13M in 2019 to $106M in 2025, growth of about 42.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 66% over three years (dilution for shareholders). It spends 12% of revenue on research and development.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Interest covered more than 5 times
- Pays a dividend
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148M | $106M | $24M | $27M | $10M | $29M | $13M | $13M | $0 | — | — |
| Net income | $75M | $83M | -$106M | -$46M | -$27M | -$9M | -$13M | -$25M | -$56M | -$43M | -$17M |
| Free cash flow | $38M | -$2M | -$70M | -$34M | -$19M | $10M | -$2M | -$24M | -$54M | -$33M | -$30M |
| EPS (diluted) | $1.22 | $1.35 | $-2.28 | $-1.30 | $-0.78 | $-2.11 | $-3.21 | $-13.23 | $-50.40 | $-47.36 | $-18.08 |
| Net margin | 50.7% | 78.2% | -446.8% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — |
| ROIC | — | -27.7% | -68.8% | -47.0% | -55.6% | 5.9% | -177.0% | -400.6% | -375.1% | -94.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $23.00, 153% above the current price; targets range from $18.00 to $35.00; the consensus rating is “Strong buy”; expected EPS is $1.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Zevra Therapeutics’s P/E ratio?
About 7.4, based on the last twelve months of diluted earnings per share (forward P/E about 10.2).
Is Zevra Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zevra Therapeutics pay a dividend?
Not currently.
Is Zevra Therapeutics a good stock to buy?
We do not give buy or sell advice. Zevra Therapeutics scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.